Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMRN: Amarin Corporation plc -- Ignore unavailable to you. Want to Upgrade?

To: ariadough who wrote (33)	3/22/2012 9:30:51 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 49

‘598 patent application cover "pharmaceutical composition" (containing high purity E-EPA, >96%) to be used in treatment of the psychiatric/neurological conditions, not high triglyceride. High triglyceride condition is FIRST TIME mentioned in 12/769,885 application (protective oxidation composition, weak claim 44.) '598 is "child" patent application that continue on OLD (1999) parent patent, originally filed for NEUROLOGICAL condition, now licensed to Prismic. So, You can ask fellow longs on any public board (or analyst at Jefferies) : Will '589 patent EVER be included in "Orange book", IF 101 gain marketing authorization?